Ascelia Pharma AB

Equities

ACE

SE0010573113

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2024-06-20 EDT			5-day change	1st Jan Change
9.47 ^SEK	+8.35%		+2.60%	+181.01%

06-17	Transcript : Ascelia Pharma AB - Special Call
05-21	Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024

Ascelia Pharma AB Announces Dorthe da Graca Thrige Leaving as Chief Operation Officer

October 25, 2019 at 08:30 am

Ascelia Pharma AB (publ) announced that Ascelia Pharma and the company's Chief Operation Officer (COO) Dorthe da Graca Thrige have reached an agreement that she will be leaving the company. Her duties will be divided between other senior employees in Ascelia Pharma.

Latest news about Ascelia Pharma AB

Transcript : Ascelia Pharma AB - Special Call	06-17
Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 21, 2024	05-21
Transcript : Ascelia Pharma AB, Q1 2024 Earnings Call, May 16, 2024	05-16
Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-16	CI
Transcript : Ascelia Pharma AB - Special Call	05-07
Ascelia Pharma AB Successfully Meets Primary Endpoint with Strong Headline Results in Orvigance Phase 3 Study	05-02	CI
Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024	04-10	CI
Ascelia Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-09	CI
Transcript : Ascelia Pharma AB, Q4 2023 Earnings Call, Feb 09, 2024	02-09
Ascelia Pharma AB Announces Start of Image Reading Phase and Re- Confirms Phase 3 SPARKLE Results by May 2024	12-07	CI
Transcript : Ascelia Pharma AB, Q3 2023 Earnings Call, Nov 08, 2023	11-08
Ascelia Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
OptiCept Technologies Names New CFO	23-10-20	MT
Transcript : Ascelia Pharma AB, H1 2023 Earnings Call, Aug 23, 2023	23-08-23
Transcript : Ascelia Pharma AB, H1 2023 Earnings Call, Aug 18, 2023	23-08-18
Ascelia Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Transcript : Ascelia Pharma AB - Special Call	23-08-08
Ascelia Pharma AB Announces Re-Evaluation Required After Intra-Reader Inconsistency in Scoring of Images from Phase 3 Study SPARKLE	23-08-07	CI
Transcript : Ascelia Pharma AB, Q1 2023 Earnings Call, May 11, 2023	23-05-11
Transcript : Ascelia Pharma AB, Q1 2023 Earnings Call, May 11, 2023	23-05-11
Ascelia Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-11	CI
Transcript : Ascelia Pharma AB - Special Call	23-03-30
Ascelia Pharma AB Announces Demise of René Spogárd, Member of the Board of Directors	23-03-13	CI
Ascelia Pharma AB Announces the Decision of the US Patent and Trademark Office to Allow the Issuance of a Third Patent Covering the Composition of Oncoral	23-03-13	CI
Ascelia Pharma Achieves Last Patient Last Visit in the Orviglance Phase 3 Sparkle Study Which Now Includes 85 Completed Patients	23-03-03	CI

Chart Ascelia Pharma AB

Duration

Period

More charts

Company Profile

Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q2 2024 Earnings Release

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ASCELIA PHARMA AB	+181.01%	30.33M
MODERNA, INC.	+34.14%	51.12B
IQVIA HOLDINGS INC.	-6.54%	39.4B
LONZA GROUP AG	+34.92%	38.48B
ICON PUBLIC LIMITED COMPANY	+12.62%	26.36B
CELLTRION, INC.	-12.11%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-13.43%	20.96B
UNITED THERAPEUTICS CORPORATION	+43.73%	14.02B
MEDPACE HOLDINGS, INC.	+31.81%	12.49B
BIO-TECHNE CORPORATION	-4.54%	11.61B

Other Biotechnology & Medical Research